Nonsurgical treatment options for basal cell carcinoma - Focus on advanced disease

Journal of Drugs in Dermatology

Volumn 12, Issue 12, 2013, Pages 1371-1378

  Goldenberg, Gary ^a   Hamid, Omid ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Angeles Clinic and Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMIQUIMOD; VISMODEGIB; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; BASAL CELL CARCINOMA; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CONSERVATIVE TREATMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; PHOTODYNAMIC THERAPY; RECURRENCE RISK; REVIEW; SYSTEMIC THERAPY; CHEMOSURGERY; METHODOLOGY; PATHOLOGY; PHOTOCHEMOTHERAPY; RADIOTHERAPY; SKIN TUMOR; TUMOR RECURRENCE; UNITED STATES;

ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; HUMANS; MOHS SURGERY; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; RADIOTHERAPY; SKIN NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84890960311     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol. 2006;19(Suppl 2):S127-S147.
2. Dourmishev LA, Rusinova D, Botev I. Clinical variants, stages, and management of basal cell carcinoma. Indian Dermatol Online J. 2013;4(1):12-17.
3. Kasper M, Jaks V, Hohl D, Toftgard R. Basal cell carcinoma - molecular - biology and potential new therapies. J Clin Invest. 2012;122(2):455-463.
4. National Cancer Institute at the National Institutes of Health. Skin cancer. Available at www.cancer.gov/cancertopics/types/skin. Accessed June 19, 2013.
5. World Health Organization (WHO). Ultra violet radiation and the INTERSUN Programme. Skin cancer: How commo is skin cancer? Available at www. who.int/uv/faq/skincancer/en/index1.html#. Accessed July 24, 2013.
6. Cakir BO, Adamson P, Cingi C. Epidemiology and economic burden of nonmelanoma skin cancer. Facial Plast Surg Clin North Am. 2012;20(4):419-422.
7. Kim RH, Armstrong AW. Nonmelanoma skin cancer. Dermatol Clin.2012;30(1):125-139, ix.
8. Wu TP, Stein JA. Nonmelanoma skin cancer in young women. J Drugs Dermatol. 2013;12(5):568-572.
9. Chen JG, Fleischer AB Jr, Smith ED, et al. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg. 2001;27(12):1035-1038.
10. Soyer HP, Rigel DS, Wurm EMT. Actinic keratosis, basal cell carcinoma and squamous cell carcinoma. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 2. Third ed. New York: Elsevier Saunders; 2012:1773-1794.
11. Frankel A, Goldenberg G. Presentations and treatment of basal cell carcinoma: a review. Cutaneous Oncology Today. 2011 (October):5-9.
12. Chren MM, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2013;133(5):1188-1196.
13. Griffiths RW, Suvarna SK, Stone J. Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg. 2005;58(6):795-805
14. Silverman MK, Kopf AW, Bart RS, Grin CM, Levenstein MS. Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. J Dermatol Surg Oncol. 1992;18(6):471-476.
15. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Basal Cell and Squamous Cell Skin Cancers. V.2.2012. Available at www.nccn.org.
16. Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol. 2007;4(8):462-469.
17. Sterry W, European Dermatology Forum Guideline C. Guidelines: the management of basal cell carcinoma. Eur J Dermatol. 2006;16(5):467-475.
18. Bogelund FS, Philipsen PA, Gniadecki R. Factors affecting the recurrence rate of basal cell carcinoma. Acta Derm Venereol. 2007;87(4):330-334.
19. Kyrgidis A, Vahtsevanos K, Tzellos TG, et al. Clinical, histological and demographic predictors for recurrence and second primary tumours of head and neck basal cell carcinoma. A 1062 patient-cohort study from a tertiary cancer referral hospital. Eur J Dermatol. 2010;20(3):276-282.
20. Lindberg-Larsen R, Solvsten H, Kragballe K. Evaluation of recurrence after photodynamic therapy with topical methylaminolaevulinate for 157 basal cell carcinomas in 90 patients. Acta Derm Venereol. 2012;92(2):144-147.
21. Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet.2010;375(9715):673-685.
22. Netscher DT, Leong M, Orengo I, Yang D, Berg C, Krishnan B. Cutaneous malignancies: melanoma and nonmelanoma types. Plast Reconstr Surg. 2011;127(3):37e-56e.
23. Randle HW. Basal cell carcinoma. Identification and treatment of the highrisk patient. Dermatol Surg. 1996;22(3):255-261.
24. Samarasinghe V, Madan V. Nonmelanoma skin cancer. J Cutan Aesthet Surg.2012;5(1):3-10.
25. Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev. 2004;23(3-4):389-402.
26. Farmer ER, Helwig EB. Metastatic basal cell carcinoma: a clinicopathologic study of seventeen cases. Cancer. 1980;46(4):748-757.
27. Ganti AK, Kessinger A. Systemic therapy for disseminated basal cell carcinoma: an uncommon manifestation of a common cancer. Cancer Treat Rev. 2011;37(6):440-443.
28. Jackson R, Adams RH. Horrifying basal cell carcinoma: a study of 33 cases and a comparison with 435 non-horror cases and a report on four metastatic cases. J Surg Oncol. 1973;5(5):431-463.
29. Moser S, Borm J, Mihic-Probst D, Jacobsen C, Kruse Gujer AL. Metastatic basal cell carcinoma: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 January 10 [Epub ahead of print].
30. Vu A, Laub D Jr. Metastatic basal cell carcinoma: a case report and review of the literature. Eplasty. 2011;11:ic8.
31. Wysong A, Aasi SZ, Tang JY. Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011. JAMA Dermatol. 2013;149(5):615-616.
32. Ermertcan AT, Hellings PW, Cingi C. Nonmelanoma skin cancer of the head and neck: nonsurgical treatment. Facial Plast Surg Clin North Am. 2012;20(4):445-454.
33. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol. 2006;45(5):489-498.
34. Alam M, Nanda S, Mittal BB, Kim NA, Yoo S. The use of brachytherapy in the treatment of nonmelanoma skin cancer: a review. J Am Acad Dermatol. 2011;65(2):377-388.
35. Avril MF, Auperin A, Margulis A, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer. 1997;76(1):100-106.
36. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2007(1):CD003412.
37. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989;15(3):315-328.
38. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol. 1999;135(10):1177-1183.
39. Silverman MK, Kopf AW, Gladstein AH, Bart RS, Grin CM, Levenstein MJ. Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy. J Dermatol Surg Oncol. 1992;18(7):549-554.
40. Petit JY, Avril MF, Margulis A, et al. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast Reconstr Surg. 2000;105(7):2544-2551.
41. Fangman WL, Cook JL. Postradiation sarcoma: case report and review of the potential complications of therapeutic ionizing radiation. Dermatol Surg. 2005;31(8 Pt 1):966-972.
42. Guerin S, Dupuy A, Anderson H, et al. Radiation dose as a risk factor for malignant melanoma following childhood cancer. Eur J Cancer. 2003;39(16):2379-2386.
43. Lichter MD, Karagas MR, Mott LA, Spencer SK, Stukel TA, Greenberg ER. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol. 2000;136(8):1007-1011.
44. Botto N, Rogers G. Nontraditional management of basal cell carcinoma. J Drugs Dermatol. 2013;12(5):525-532.
45. Aldara Cream [package insert]; Bristol, TN: Graceway Pharmaceuticals, LLC; 2010. Available at www.accessdata.fda.gov/drugsatfda-docs/ label/2010/020723s0022lbl.pdf. .
46. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722-733.
47. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehiclecontrolled phase III study in Europe. Br J Dermatol. 2005;152(5):939-947.
48. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol. 2008;18(6):677-682.
49. Quirk C, Gebauer K, De'Ambrosis B, Slade HB, Meng TC. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis. 2010;85(6):318-324.
50. Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. Br J Dermatol. 2012;167(4):733-756.
51. Shumack S, Gebauer K, Quirk C, Macdonald K, Walters SA, Owens M. 5% imiquimod cream for the treatment of large superficial basal cell carcinoma. Arch Dermatol. 2004;140(10):1286-1287.
52. Eigentler TK, Kamin A, Weide BM, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol. 2007;57(4):616-621.
53. Peris K, Campione E, Micantonio T, Marulli GC, Fargnoli MC, Chimenti S. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg. 2005;31(3):318-323.
54. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002;138(9):1165-1171.
55. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002;147(6):1227-1236.
56. Butler DF, Parekh PK, Lenis A. Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal cell carcinomas before Mohs micrographic surgery: a randomized, double blind, vehicle-controlled study. Dermatol Surg. 2009;35(1):24-29.
57. Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg. 2006;32(1):63-69.
58. Carneiro RC, de Macedo EM, Matayoshi S. Imiquimod 5% cream for the treatment of periocular Basal cell carcinoma. Ophthal Plast Reconstr Surg. 2010;26(2):100-102.
59. Leppala J, Kaarniranta K, Uusitalo H, Kontkanen M. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand. 2007;85(5):566-568.
60. Prokosch V, Thanos S, Spaniol K, Stupp T. Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids. Graefes Arch Clin Exp Ophthalamol. 2011;249(1):121-125.
61. Efudex (topical fluorouracil solution or cream) package insert. Available at http://www.drugs.com/pro/efudex.html. Accessed September 9, 2013.
62. Efudex (topical fluorouracil solution or cream) package insert. Available at http://skincancer.about.com/od/treatmentoptions/a/5fluorouracil.html. Accessed September 9, 2013.
63. Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial Basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg. 2007;33(4):433-439; discussion 440.
64. Miller BH, Shavin JS, Cognetta A, et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. J Am Acad Dermatol. 1997;36(1):72-77.
65. Epstein E. Fluorouracil paste treatment of thin basal cell carcinomas. Arch Dermatol. 1985;121(2):207-213.
66. Reymann F. Treatment of basal cell carcinoma of the skin with 5-fluorouracil ointment. A 10-year follow-up study. Dermatologica. 1979;158(5):368-372.
67. Fallen RS, Gooderham M. Ingenol mebutate: an introduction. Skin Therapy Lett. 2012;17(2):1-3.
68. Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010;51(2):99-105.
69. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007;56(1):125-143.
70. Morton CA, McKenna KE, Rhodes LE, British Association of Dermatologists Therapy G, Audit S, the British Photodermatology G. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2008;159(6):1245-1266.
71. Haller JC, Cairnduff F, Slack G, et al. Routine double treatments of superficial basal cell carcinomas using aminolaevulinic acid-based photodynamic therapy. Br J Dermatol. 2000;143(6):1270-1275.
72. Basset-Seguin N, Bissonnette R, Girard C, et al. Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate-photodynamic therapy. J Eur Acad Dermatol Venereol. 2013 April 13. [Epub ahead of print].
73. American Cancer Society. Photodynamic therapy. Available at http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/ photodynamic-therapy. Accessed September 9, 2013.
74. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008;18(5):547-553.
75. Szczylik C, Demkow T, Staehler WM, et al. Randomized phase II trial of firstline treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol. 2007;25(18S). Abstract 5025.
76. Rhodes LE, de Rie M, Enstrom Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol. 2004;140(1):17-23.
77. Horn M, Wolf P, Wulf HC, et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol. 2003;149(6):1242-1249.
78. Vinciullo C, Elliott T, Francis D, et al. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. Br J Dermatol. 2005;152(4):765-772.
79. Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur AcadDermatol Venereol. 2008;22(11):1302-1311.
80. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143(9):1131-1136.
81. Erivedge [package insert]; South San Francisco, CA: Genentech USA, Inc.; 2012.Available at www.accessdata.fda.gov/drugsatfda-docs/label/2012/203388lbl. pdf.
82. Axelson M, Liu K, Jiang X, et al. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res. 2013;19(9):2289-2293.
83. Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol. 2005;152(1):43-51.
84. Kiwilsza M, Sporniak-Tutak K. Gorlin-Goltz syndrome - a medical condition requiring a multidisciplinary approach. Med Sci Monit. 2012;18(9):RA145-153.
85. Caro I, Low JA. The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment. Clin Cancer Res. 2010;16(13):3335-3339.
86. de Zwaan SE, Haass NK. Genetics of basal cell carcinoma. Australas J Dermatol. 2010;51(2):81-92; quiz 93-84.
87. Queiroz KC, Spek CA, Peppelenbosch MP. Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors. Drug Resist Updat. 2012;15(4):211-222.
88. Coker DD, Elias EG, Viravathana T, McCrea E, Hafiz M. Chemotherapy for metastatic basal cell carcinoma. Arch Dermatol. 1983;119(1):44-50.
89. Bason MM, Grant-Kels JM, Govil M. Metastatic basal cell carcinoma: response to chemotherapy. J Am Acad Dermatol. 1990;22(5 Pt 2):905-908.
90. Carneiro BA, Watkin WG, Mehta UK, Brockstein BE. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest. 2006;24(4):396-400.
91. Guthrie TH Jr, McElveen LJ, Porubsky ES, Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985;55(8):1629-1632.
92. Jefford M, Kiffer JD, Somers G, Daniel FJ, Davis ID. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg. 2004;74(8):704-705.
93. Moeholt K, Aagaard H, Pfeiffer P, Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma - a review of the literature. Acta Oncol. 1996;35(6):677-682.
94. Wieman TJ, Shively EH, Woodcock TM. Responsiveness of metastatic basalcell carcinoma to chemotherapy. A case report. Cancer. 1983;52(9):1583- 1585.
95. Wood LD, Ammirati CT. An overview of Mohs micrographic surgery for the treatment of basal cell carcinoma. Dermatol Clin. 2011;29(2):153-160, vii.
96. Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett. 2009;19(19):5576-5581.
97. Amin SH, Tibes R, Kim JE, Hybarger CP. Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma. Laryngoscope. 2010;120(12):2456-2459.
98. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502-2511.
99. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164-1172.
100. Lorusso PM, Jimeno A, Dy G, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(17):5774-5782.
101. LoRusso PM, Piha-Paul SA, Mita M, et al. Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drugdrug interaction potential. Cancer Chemother Pharmacol. 2013;71(1):193-202.
102. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179.
103. Hall JM, Bell ML, Finger TE. Disruption of sonic hedgehog signaling alters growth and patterning of lingual taste papillae. Dev Biol. 2003;255(2):263-277.
104. Liu HX, Maccallum DK, Edwards C, Gaffield W, Mistretta CM. Sonic hedgehog exerts distinct, stage-specific effects on tongue and taste papilla development. Dev Biol. 2004;276(2):280-300.
105. Chiang C, Swan RZ, Grachtchouk M, et al. Essential role for Sonic hedgehog during hair follicle morphogenesis. Dev Biol. 1999;205(1):1-9.
106. Choi SS, Omenetti A, Syn WK, Diehl AM. The role of Hedgehog signaling in fibrogenic liver repair. Int J Biochem Cell Biol. 2011;43(2):238-244.
107. Teglund S, Toftgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta. 2010;1805(2):181-208.
108. Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients wiuth advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study. Poster presented at the 2013 American Society of Clinical Oncology (ASCO) meeting held in Chiacgo, IL, May 31-June 4, 2013.
109. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180-2188.
110. Gross KG, Sofen H, Goldberg LH, et al. Preliminary results of a Phase 2 trial evaluating efficacy and saefty of vismodegib (GDC-0449) in operable basal cell carcinoma. J Invest Dermatol 2012;132:S92; abstr 543.